Charcot-Marie-Tooth Disease Market Analysis & Forecast: 2026-2033

Charcot-Marie-Tooth Disease Market Size and Share Analysis - 2026 To 2033

The global Charcot-Marie-Tooth disease market size is estimated to reach USD 2,271.5 Mn in 2026 and is projected to grow at a CAGR of 23.4% during the forecast period (2026-2033), surpassing USD 9,896.5 Mn by 2033. This growth is attributable to increasing prevalence of inherited peripheral neuropathies, rising awareness and early diagnosis of rare genetic disorders, and advancements in gene therapy and RNA-based therapeutics.

Key Takeaways from the Charcot-Marie-Tooth Disease Market Report

• CMT 1 is expected to lead the market with a share of 52% in 2026 because of its high prevalence and continued focus on research as well as clinical trials and drug development. CMT1 accounts for about 50% of all Charcot-Marie-Tooth disease cases, creating strong demand for Charcot-Marie-Tooth Disease therapeutics.
• Anticonvulsants are projected to account for the largest market share of 29% in 2026 due to their widespread use in managing chronic neuropathic pain associated with CMT. Approximately 80% of individuals with Charcot-Marie-Tooth disease experience pain, as per the Charcot-Marie-Tooth Association, leading to higher demand for gabapentinoids such as gabapentin and pregabalin.
• North America is forecast to dominate the global Charcot-Marie-Tooth disease industry with a share of 44% in 2026 due to high diagnosis rates, established rare disease treatment infrastructure, favorable reimbursement, and active clinical research.
• Asia Pacific, holding a share of 18% in 2026, is posed to emerge as the fastest growing market for Charcot-Marie-Tooth disease therapeutics during the forecast period, thanks to increasing awareness and diagnosis of rare neurological disorders, expanding access to advanced genetic testing, and rising healthcare expenditure.

Charcot-Marie-Tooth Disease Market Overview

The global Charcot-Marie-Tooth disease market is poised to exhibit robust growth during the forecast period. This is primarily due to increasing prevalence of Charcot-Marie-Tooth disease, growing awareness of rare genetic disorders, and continuous advancements in genetic diagnostics that enable earlier and more accurate disease identification.

Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders. More than 100 genes have been identified as being associated with CMT, and mutations in these genes can cause one or more subtypes of the disease. In addition, several genes may be associated with the same type of CMT.

More than half of CMT cases are caused by a duplication of the PMP22 gene on chromosome 17. There are several types of CMT, including CMT1, which is caused by abnormalities of the myelin sheath; CMT2, which is characterized by abnormalities of the peripheral nerve axons; and CMT3, also known as Dejerine-Sottas disease, a severe demyelinating neuropathy that typically begins in infancy. Increasing diagnosed cases of these diseases are providing stimulus for the growth of Charcot-Marie-Tooth disease market.

Increasing adoption of precision medicine is expected to boost Charcot-Marie-Tooth disease market growth during the forecast period. Healthcare professional and patients are gradually shifting their preference towards therapies targeting specific genetic mutations such as PMP22, MFN2, MPZ, and GJB1.

 Segmental Insights 

To learn more about this report, Request Free Sample

Which Disease Type Dominates the Charcot-Marie-Tooth Disease Market?

CMT 1 to Account for Over Half of the Market Share in 2026

According to Coherent Market Insights’ latest Charcot-Marie-Tooth Disease Market analysis, CMT 1 is set to lead the market, capturing a share of 52% in 2026. This dominance is attributable to high prevalence of CMT1, especially CMT1A, which is caused by duplication of the PMP22 gene and accounts for the majority of diagnosed Charcot-Marie-Tooth disease cases worldwide.

The Charcot-Marie-Tooth Association (CMTA)’s New Genetic Landscape Analysis found that CMT1A accounts for up to 67.5% of genetically confirmed CMT cases, making it the most common subtype. As a result, pharmaceutical companies and academic researchers prioritize the development of therapies for this subtype, supporting the segment’s leading market position.

Growing awareness of inherited peripheral neuropathies, increasing availability of advanced genetic testing, and earlier diagnosis are also boosting segment growth. In addition, ongoing research into gene-targeted therapies, disease-modifying treatments, and improved supportive care is driving greater clinical interest and investment in CMT1. This will also help CMT 1 segment to retain its dominant position during the forecast period.

Which Drug Type Accounts for the Largest Charcot-Marie-Tooth Disease Market Share?

Anticonvulsants Set to Account for the Largest Market Share in 2026 

To learn more about this report, Request Free Sample

By drug type, anticonvulsants are expected to account for the largest market share of 29% in 2026. This is mostly due to their widespread use in managing neuropathic pain, one of the most common and debilitating symptoms experienced by patients with Charcot-Marie-Tooth (CMT) disease.

Medications such as gabapentin and pregabalin are frequently prescribed to reduce nerve pain, improve patient comfort, and enhance quality of life. Their established safety profile, strong clinical acceptance, and availability as generic formulations also contribute to their leading market position.

A 2025 multicenter real-world survey involving 2,841 patients with neuropathic pain reported that gabapentinoid-based therapies (pregabalin and gabapentin) were the preferred treatment prescribed by neurologists, either alone or in combination with antidepressants, across multiple neuropathic pain conditions. In addition, increasing diagnosis rates, growing awareness of CMT, and rising demand for symptomatic treatment continue to drive adoption of anticonvulsants across both hospital and outpatient settings.

Charcot-Marie-Tooth Disease Market Growth Drivers

Rising Prevalence of Charcot-Marie-Tooth Disease Worldwide

Increasing prevalence of Charcot-Marie-Tooth disease and improved diagnosis of inherited neuropathies are expected to boost growth of Charcot-Marie-Tooth disease market during the forecast period. Charcot-Marie-Tooth disease is one of the most common inherited peripheral neuropathies. According to the Charcot-Marie-Tooth Association, CMT affects an estimated 2.6–3 million people worldwide. This, in turn, is fueling demand for Charcot-Marie-Tooth disease treatments.

Rising adoption of next-generation sequencing (NGS), genetic screening, and molecular diagnostic technologies is improving early and accurate diagnosis. These technologies help increase the identifiable patient population eligible for treatment and clinical trials, thereby creating a favourable environment for the expansion of the Charcot-Marie-Tooth disease market.

Charcot-Marie-Tooth Disease Market Opportunities

Increasing Investment in Rare Disease Research

Governments, academic institutions, and private investors are allocating greater funding to rare neurological diseases. Research grants, venture capital investment, and collaborations between biotechnology companies and research organizations are accelerating drug discovery and clinical development. This, in turn, is expected to create lucrative growth opportunities for the Charcot-Marie-Tooth disease market during the forecast period.

Charcot-Marie-Tooth Disease Market Trends

Strong Pipeline of Disease-modifying Therapies

Rising transition toward disease-modifying therapies is a key growth-shaping trend in the Charcot-Marie-Tooth disease market. The market is shifting from symptomatic management toward disease-modifying approaches. Pharmaceutical and biotechnology companies are actively developing gene therapies, RNA-based therapeutics, antisense oligonucleotides, and small-molecule therapies that target the underlying genetic causes of CMT. This is expected to create strong future growth opportunities in the market during the forthcoming period.

Current Events and Their Impact on the Charcot-Marie-Tooth Disease Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Regional Insights 

To learn more about this report, Request Free Sample

North America Remains at the Epicenter of Charcot-Marie-Tooth Disease Market Growth

North America is expected to account for around a 44% share of the global Charcot-Marie-Tooth (CMT) disease market in 2026. This dominance is attributed to strong genetic testing capabilities, advanced neurology care infrastructure, and early adoption of emerging therapies such as gene-based and RNA-targeted treatments. The region also benefits from high awareness of rare neurological disorders and strong clinical research activity focused on disease-modifying approaches.

Rising recognition and diagnosis of inherited neuropathies like CMT, supported by improved genomic screening, is expected to boost the growth of the North America Charcot-Marie-Tooth disease market. According to the NIH/National Institute of Neurological Disorders and Stroke (NINDS), Charcot-Marie-Tooth disease affects approximately 1 in 2,500 people globally. This growing diagnosed population is fueling demand for advanced therapies for Charcot-Marie-Tooth disease.

Asia Pacific Charcot-Marie-Tooth Disease Market Trends

Asia Pacific is anticipated to emerge as a highly lucrative market for Charcot-Marie-Tooth disease drug manufacturers during the forecast period, holding a global market share of 18% in 2026. This is mostly due to improving access to genetic testing, rising neurological disorder awareness, and expanding healthcare infrastructure. Neurological disorders accounted for nearly 10% of the total disease burden in India. Increasing investments in rare disease diagnosis and growing adoption of advanced neurology care are also supporting market expansion.

Rising ability to detect inherited neurological conditions earlier, which is expanding the diagnosed CMT patient base in the region, is set to boost market growth. Similarly, growing awareness among healthcare professionals and patients is likely to create a conducive environment for the growth of Asia Pacific Charcot-Marie-Tooth disease market in the coming years.

Charcot-Marie-Tooth Disease Market Outlook – Country-wise

U.S. Charcot-Marie-Tooth Disease Market Forecast

The United States is forecast to remain a leading market for Charcot-Marie-Tooth (CMT) Disease therapeutics during the projection period. This is due to advanced neurology care systems, strong adoption of genetic testing, and rapid uptake of emerging disease-modifying approaches such as gene and RNA-based therapies. High clinical research activity and early access to innovative treatments are further strengthening patient management and diagnosis in the country.

China Charcot-Marie-Tooth Disease Market Trends

The Charcot-Marie-Tooth disease market in China is projected to grow rapidly during the forecast period. This can be attributed to increasing incidence of Charcot-Marie-Tooth disease, improving access to neurology and genetic diagnostic services, and expanding healthcare infrastructure. Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, with an estimated prevalence of 17.7–40 cases per 100,000 population. Rising awareness of rare neurological disorders and gradual adoption of advanced treatment approaches are also supporting better diagnosis and disease management in the country.

Who are the Major Companies in the Charcot-Marie-Tooth Disease Market?

Some of the major players in Charcot-Marie-Tooth Disease Market are Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.

Key Strategies Adopted by Industry Players

Top manufacturers of Charcot-Marie-Tooth disease drugs are adopting various organic and inorganic strategies to boost their sales as well as gain a competitive edge over the industry. These include new product launches and approvals, investments in R&D, clinical trials, mergers, acquisitions, distribution agreements, partnerships, collaborations, and joint ventures.

• In February 2026, NMD Pharma announced topline results from its Phase 2a SYNAPSE-CMT study evaluating ignaseclant in Charcot-Marie-Tooth disease types 1 and 2. The results showed improvement in several measured outcomes in the study.
• In March 2026, ReviR Therapeutics announced the first human dosing of RTX-117 in a Phase 1 clinical trial in China. It is an investigational drug for Charcot-Marie-Tooth disease that targets multiple CMT subtypes.

Market Report Scope 

Analyst Opinion (Expert Opinion)

• Charcot-Marie-Tooth (CMT) disease is a high unmet medical need. There is currently no approved cure, so treatment mainly focuses on symptom management through physical therapy, orthopedic devices, surgery, and pain management. This creates strong demand for disease-modifying therapies and innovative genetic treatments.
• Genetic testing is becoming more important for CMT diagnosis. More than 100 genes have been linked to the disease, making advanced genetic sequencing essential for accurate diagnosis and personalized treatment approaches. This is increasing demand for genetic testing services and precision medicine solutions.
• Growing research in gene therapy and rare disease drug development is also expected to foster CMT disease market growth during the forthcoming period. Increasing investments in gene-editing technologies and targeted therapies are expanding the clinical pipeline, which could improve long-term treatment options and support future market growth.
• CMT is one of the most common inherited neuromuscular disorders, affecting about 1 in every 2,500 people worldwide. This relatively high prevalence of a rare genetic disease supports continued investment in diagnostics, rehabilitation, and novel therapies, creating sustained opportunities for UV Lamps Market expansion.

Market Segmentation

• By Disease Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • CMT 1
  • CMT 2
  • CMT 3
  • Others
• By Drug Type Insights ( Revenue, USD Mn, 2021 - 2033)
  • Nonsteroidal anti-inflammatory drugs
  • Cyclooxygenase-2 inhibitors
  • Tricyclic antidepressants
  • Anticonvulsants
  • Analgesics
  • Pipeline Drug
• By Distribution Channel Insights ( Revenue, USD Mn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region Insights ( Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  •  Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  •  Africa
    • North Africa
    • Central Africa
    • South Africa

Sources

Primary Research Interviews

• Neurologists specializing in peripheral neuropathies
• Clinical geneticists
• Orthopedic surgeons
• Rehabilitation medicine specialists
• Hospital pharmacists
• Academic researchers
• Biotechnology and pharmaceutical company executives
• Clinical trial investigators
• Healthcare distributors and procurement managers
• Key opinion leaders (KOLs)

Databases

• PubMed
• MEDLINE
• Embase
• Scopus
• ClinicalTrials.gov
• Orphanet
• Europe PMC
• Cochrane Library
• NIH Genetic Testing Registry (GTR)
• NCBI Gene Database

Magazines

• Neurology Today
• Rare Revolution Magazine
• Pharmaceutical Executive
• MedTech Outlook
• BioPharm International
• Genetic Engineering & Biotechnology News (GEN)

Journals

• Journal of the Peripheral Nervous System
• Neurology
• Brain
• Journal of Neurology
• Muscle & Nerve
• Journal of Neuromuscular Diseases
• Orphanet Journal of Rare Diseases
• The Lancet Neurology
• Nature Reviews Neurology
• Neuromuscular Disorders

Newspapers

• The Wall Street Journal
• Financial Times
• The New York Times
• The Guardian
• USA Today
• The Economic Times

Associations

• Charcot-Marie-Tooth Association (CMTA)
• Hereditary Neuropathy Foundation (HNF)
• Peripheral Nerve Society (PNS)
• Muscular Dystrophy Association (MDA)
• European Academy of Neurology (EAN)
• American Academy of Neurology (AAN)
• National Organization for Rare Disorders (NORD)
• EURORDIS – Rare Diseases Europe

Public Domain Sources

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• U.S. National Institutes of Health (NIH)
• National Institute of Neurological Disorders and Stroke (NINDS)
• National Center for Biotechnology Information (NCBI)
• ClinicalTrials.gov
• Centers for Disease Control and Prevention (CDC)
• European Commission
• Organisation for Economic Co-operation and Development (OECD)
• World Bank
• Eurostat

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years